Companies / Pulmera

Medical device company profile

Pulmera

U.S. medical device company behind CBeam, a platform that adds intraoperative 3D imaging to compatible surgical C-arms.

Medical Device Manufacturer and DeveloperDiagnostics & ImagingDiagnostic Imaging

Headquarters🇺🇸Charlotte, North Carolina, United States

FoundedNot confirmed

Commercial statusCommercially availableCommercial · U.S. 510(k)-cleared

Employees2–10LinkedIn company-size range

Estimated revenueNot confirmed

Disclosed fundingUS$2.25 millionNCI SBIR grant award over two years · September 2026

Official websitecbeam.com ↗

Company overview

Pulmera is a medical technology company headquartered in Charlotte, North Carolina, and led by CEO Kevin McGann. Its CBeam platform is designed to extend the imaging capability of compatible C-arms already installed in hospitals and ambulatory surgery centers.

CBeam combines hardware and reconstruction technology to produce intraoperative 3D images from a compatible 2D C-arm. The current website identifies the GE OEC Elite 31 cm CFD C-arm as compatible; that specification should not be read as support for every C-arm model.

The platform received U.S. 510(k) clearance in May 2026, and Pulmera reports clinical use beginning in August 2026. Its commercial focus is orthopedic and neurological surgery. An NCI-funded programme is also investigating additional compatibility and lung-biopsy applications, which are separate from an established lung-biopsy indication.

^{[1][2][3][4][5]}

Leadership

5 people

Kevin McGannChief Executive Officer ^[2]

Bryan Hartley, MDCo-founder & Chief Product Officer ^[2]

Harmeet Bedi, MDCo-founder & Chief Medical Advisor ^[2]

Nicolas RobertChief Technology Officer ^[2]

Jared SlibeckChief Commercial Officer ^[2]

Products & regulatory status How does MedTechIndex get this information?

Summary

FDA cleared C-beam under K252735 on May 22, 2026. The Class II system is intended for 3D visualization in orthopedic and neurological surgical procedures. Compatibility is model-specific rather than a blanket authorization for all C-arms. ^[1][6]

Pulmera’s September 2026 NCI award supports further research, including possible lung-nodule biopsy applications. That research programme should not be presented as an additional cleared indication. ^[1][6]

Regulatory snapshot How to read this snapshot

U.S. FDA

1+
510(k) clearances: —
De Novo grants: —
PMA approvals: —
Recall events

Latest recorded source review: 2026-11-05.

Scope: selected product families.

Commercial portfolio snapshot

Documented commercial product families.

Intraoperative 3D imaging system

CBeam 3D imaging platform ↗

Platform that adds 3D reconstruction to a compatible conventional C-arm for surgical visualization. The current manufacturer website specifies compatibility with the GE OEC Elite 31 cm CFD C-arm. ^[1][6]

Commercial · U.S. 510(k)-cleared